204 related articles for article (PubMed ID: 34371168)
1. Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion.
Corder RD; Gadi SV; Vachieri RB; Jayes FL; Cullen JM; Khan SA; Taylor DK
Acta Biomater; 2021 Oct; 134():443-452. PubMed ID: 34371168
[TBL] [Abstract][Full Text] [Related]
2. Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum.
Jayes FL; Liu B; Moutos FT; Kuchibhatla M; Guilak F; Leppert PC
Am J Obstet Gynecol; 2016 Nov; 215(5):596.e1-596.e8. PubMed ID: 27177523
[TBL] [Abstract][Full Text] [Related]
3. Linear and nonlinear rheology of liberase-treated breast cancer tumors.
Corder RD; Vachieri RB; Martin ME; Taylor DK; Fleming JM; Khan SA
Biomater Sci; 2023 Mar; 11(6):2186-2199. PubMed ID: 36744734
[TBL] [Abstract][Full Text] [Related]
4. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.
Islam MS; Afrin S; Singh B; Jayes FL; Brennan JT; Borahay MA; Leppert PC; Segars JH
Clin Transl Med; 2021 Jul; 11(7):e475. PubMed ID: 34323413
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Clinical Trial to Assess Safety and Tolerability of Injectable Collagenase in Women with Symptomatic Uterine Fibroids.
Singh B; Sims H; Trueheart I; Simpson K; Wang KC; Patzkowsky K; Wegman T; Soma JM; Dixon R; Jayes F; Voegltine K; Yenokyan G; Su SC; Leppert P; Segars JH
Reprod Sci; 2021 Sep; 28(9):2699-2709. PubMed ID: 33914296
[TBL] [Abstract][Full Text] [Related]
6. Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.
Brunengraber LN; Jayes FL; Leppert PC
Reprod Sci; 2014 Dec; 21(12):1452-9. PubMed ID: 25332216
[TBL] [Abstract][Full Text] [Related]
7. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
8. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
10. The management of uterine leiomyomas.
Lefebvre G; Vilos G; Allaire C; Jeffrey J; Arneja J; Birch C; Fortier M; Wagner MS;
J Obstet Gynaecol Can; 2003 May; 25(5):396-418; quiz 419-22. PubMed ID: 12738981
[TBL] [Abstract][Full Text] [Related]
11. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.
Segars JH; Parrott EC; Nagel JD; Guo XC; Gao X; Birnbaum LS; Pinn VW; Dixon D
Hum Reprod Update; 2014; 20(3):309-33. PubMed ID: 24401287
[TBL] [Abstract][Full Text] [Related]
12. Evidence of biomechanical and collagen heterogeneity in uterine fibroids.
Jayes FL; Liu B; Feng L; Aviles-Espinoza N; Leikin S; Leppert PC
PLoS One; 2019; 14(4):e0215646. PubMed ID: 31034494
[TBL] [Abstract][Full Text] [Related]
13. EMAS position statement: management of uterine fibroids.
Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
[TBL] [Abstract][Full Text] [Related]
14. A tissue preparation to characterize uterine fibroid tissue properties for thermal therapies.
Dillon C; Rezvani M; McLean H; Adelman M; Dassel M; Jarboe E; Janát-Amsbury M; Payne A
Med Phys; 2019 Aug; 46(8):3344-3355. PubMed ID: 31152601
[TBL] [Abstract][Full Text] [Related]
15. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study.
Hirst A; Dutton S; Wu O; Briggs A; Edwards C; Waldenmaier L; Maresh M; Nicholson A; McPherson K
Health Technol Assess; 2008 Mar; 12(5):1-248, iii. PubMed ID: 18331704
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
17. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.
Sangkomkamhang US; Lumbiganon P; Laopaiboon M; Mol BW
Cochrane Database Syst Rev; 2013 Feb; (2):CD008994. PubMed ID: 23450594
[TBL] [Abstract][Full Text] [Related]
18. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
19. [Uterine fibroids and their treatment].
Hrubosová E
Ceska Gynekol; 2011 Apr; 76(2):152-7. PubMed ID: 21650001
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
